GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (STU:7AY1) » Definitions » EV-to-FCF

Actinium Pharmaceuticals (STU:7AY1) EV-to-FCF : -3.90 (As of Jun. 05, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Actinium Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Actinium Pharmaceuticals's Enterprise Value is €143.50 Mil. Actinium Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-36.75 Mil. Therefore, Actinium Pharmaceuticals's EV-to-FCF for today is -3.90.

The historical rank and industry rank for Actinium Pharmaceuticals's EV-to-FCF or its related term are showing as below:

STU:7AY1' s EV-to-FCF Range Over the Past 10 Years
Min: -138.71   Med: -2.05   Max: 29.53
Current: -4.04

During the past 13 years, the highest EV-to-FCF of Actinium Pharmaceuticals was 29.53. The lowest was -138.71. And the median was -2.05.

STU:7AY1's EV-to-FCF is ranked worse than
100% of 378 companies
in the Biotechnology industry
Industry Median: 8.345 vs STU:7AY1: -4.04

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Actinium Pharmaceuticals's stock price is €7.305. Actinium Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.582. Therefore, Actinium Pharmaceuticals's PE Ratio for today is At Loss.


Actinium Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Actinium Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinium Pharmaceuticals EV-to-FCF Chart

Actinium Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.30 -3.38 -2.65 20.19 -1.39

Actinium Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -138.99 -2.62 -1.71 -1.39 -3.73

Competitive Comparison of Actinium Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Actinium Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinium Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's EV-to-FCF falls into.



Actinium Pharmaceuticals EV-to-FCF Calculation

Actinium Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=143.503/-36.749
=-3.90

Actinium Pharmaceuticals's current Enterprise Value is €143.50 Mil.
Actinium Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-36.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actinium Pharmaceuticals  (STU:7AY1) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Actinium Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=7.305/-1.582
=At Loss

Actinium Pharmaceuticals's share price for today is €7.305.
Actinium Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.582.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Actinium Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinium Pharmaceuticals (STU:7AY1) Business Description

Traded in Other Exchanges
Address
275 Madison Avenue, 7th Floor, New York, NY, USA, 10016
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Actinium Pharmaceuticals (STU:7AY1) Headlines

No Headlines